January 2024: The FDA accepts Lifescient’s application to open an Investigational New Animal Drug file for LS-001, an analgesic LAI for dogs. This is the first step in the process towards approval of a new medication.

November 2023: The FDA grants Lifescient a sponsor fee waiver to support the advancement of LS-001, saving the company in excess of $1 million in product development costs.

September 2023: Lifescient was interviewed by Dr. Sarah Wooten for presentation in the distinguished veterinary journal DVM360.

November 2022: Lifescient featured in the Fountain Report. Its comprehensive in-depth news and quantitative data have been guiding decision making for executives in the business of animal health since 2002.